References
- Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260–S265.
- Shelly S, Agmon-Levin N, Altman A, et al. Thymoma and autoimmunity. Cell Mol Immunol. 2011;8(3):199–202.
- Barton AD. T-cell lymphocytosis associated with lymphocyte-rich thymoma. Cancer. 1997;80(8):1409–1417.
- Lishner M, Ravid M, Shapira J, et al. Delta-T-lymphocytosis in a patient with thymoma. Cancer. 1994;74(11):2924–2929.
- Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619–1630.
- Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88(7):2375–2384.
- Jain P, Kantarjian H, Jabbour E, et al. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(de novo and blast phase CML). Am J Hematol. 2017;92(1):E3–e4.
- Takahashi N, Miura I, Saitoh K, et al. Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood. 1998;92(12):4758–4763.
- Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization Classification of Tumors of the Thymus: continuity and changes. J Thorac Oncol. 2015;10(10):1383–1395.
- Smith GP, Perkins SL, Segal GH, et al. T-cell lymphocytosis associated with invasive thymomas. Am J Clin Pathol. 1994;102(4):447–453.
- Kantarjian H, Jabbour E, Grimley J, et al. Dasatinib. Nat Rev Drug Discov. 2006;5(9):717–718.
- Chuah C, Lim TH, Lim AS, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol. 2006;24(34):e56–e58.